bluebird bio, Inc. (NASDAQ:BLUE) insider Jeffrey T. Walsh sold 4,900 shares of the business’s stock in a transaction dated Tuesday, October 10th. The shares were sold at an average price of $129.94, for a total value of $636,706.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

bluebird bio, Inc. (NASDAQ:BLUE) traded down 4.71% during mid-day trading on Wednesday, hitting $125.45. The company had a trading volume of 1,046,862 shares. bluebird bio, Inc. has a 1-year low of $37.05 and a 1-year high of $143.50. The firm’s market capitalization is $5.72 billion. The company has a 50 day moving average of $123.70 and a 200 day moving average of $101.61.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.66) by ($0.07). The business had revenue of $16.70 million for the quarter, compared to analysts’ expectations of $6.29 million. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The business’s quarterly revenue was up 977.4% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.59) earnings per share. Analysts predict that bluebird bio, Inc. will post ($6.85) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Jeffrey T. Walsh Sells 4,900 Shares of bluebird bio, Inc. (BLUE) Stock” was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/10/11/jeffrey-t-walsh-sells-4900-shares-of-bluebird-bio-inc-blue-stock.html.

A number of hedge funds have recently modified their holdings of BLUE. QS Investors LLC grew its holdings in bluebird bio by 70.7% in the second quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 500 shares during the last quarter. Bank of Montreal Can grew its holdings in bluebird bio by 118.9% in the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock worth $176,000 after purchasing an additional 911 shares during the last quarter. Turner Investments LLC purchased a new position in bluebird bio in the second quarter worth $184,000. SG Americas Securities LLC grew its holdings in bluebird bio by 17.9% in the second quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 295 shares during the last quarter. Finally, Fairfield Bush & CO. purchased a new position in bluebird bio in the second quarter worth $210,000.

A number of research analysts recently issued reports on BLUE shares. Morgan Stanley restated an “equal weight” rating and set a $105.00 price target (up previously from $91.00) on shares of bluebird bio in a report on Wednesday, June 14th. Standpoint Research restated a “reduce” rating and set a $110.00 price target on shares of bluebird bio in a report on Friday, June 16th. BidaskClub upgraded bluebird bio from a “buy” rating to a “strong-buy” rating in a report on Friday, June 23rd. Wedbush restated an “outperform” rating and set a $100.00 price target (down previously from $121.00) on shares of bluebird bio in a report on Friday, June 23rd. Finally, Cowen and Company restated a “buy” rating on shares of bluebird bio in a report on Friday, June 23rd. Three analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company. bluebird bio presently has a consensus rating of “Hold” and a consensus target price of $118.81.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.